文献速递病毒性肝炎

血清HBV RNA可预测HBeAg阳性慢性乙型肝炎患者对聚乙二醇干扰素α-2a的应答

Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2018-01-01

研究回顾性分析了两项大型随机对照试验中接受聚乙二醇干扰素α-2a治疗的HBeAg阳性慢性乙型肝炎患者血清样本,共131例。结果显示,获得HBeAg血清学转换的患者在各时间点HBV RNA水平均显著较低,治疗第12周和第24周的HBV RNA水平对HBeAg血清学转换有良好预测能力(ROC曲线下面积>0.75,P<.001)。第12周HBV RNA>5.5 log10 copies/mL可识别30%的无应答者(阴性预测值>90%)。

要点

  • 治疗第12周和第24周HBV RNA水平可预测HBeAg血清学转换,ROC曲线下面积>0.75。
  • 第12周HBV RNA>5.5 log10 copies/mL可识别30%无应答者,阴性预测值>90%。
  • 获得HBeAg血清学转换的患者在各时间点HBV RNA水平均显著较低。

核心结论

  • 血清HBV RNA是接受聚乙二醇干扰素α-2a治疗的HBeAg阳性慢性乙型肝炎患者HBeAg血清学转换的早期预测指标。

研究设计与样本

  • 回顾性分析两项大型随机对照试验中接受聚乙二醇干扰素α-2a治疗的HBeAg阳性慢性乙型肝炎患者的血清样本。
  • 共纳入131例受试者(70%男性,96%亚洲人,35%HBV基因型B,61%基因型C),其中76例单用聚乙二醇干扰素α-2a,55例联合拉米夫定。
  • 采用实时聚合酶链反应检测HBV RNA水平,用受试者工作特征(ROC)分析评估各生物标志物预测治疗结束后24周HBeAg血清学转换的能力。

主要发现

  • 获得HBeAg血清学转换的患者在所有时间点的中位HBV RNA水平均显著较低。
  • 治疗第12周和第24周的HBV RNA水平对HBeAg血清学转换显示良好预测能力(ROC曲线下面积>0.75,P<.001)。
  • 第12周HBV RNA截断值>5.5 log10 copies/mL可识别30%的无应答者(阴性预测值>90%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis B virus (HBV) RNA is a novel serum biomarker that has the potential to predict treatment response in patients with chronic hepatitis B. We explored whether HBV RNA serum levels can predict hepatitis B e antigen (HBeAg) seroconversion in patients treated with peginterferon alfa-2a. METHODS: Serum samples from HBeAg-positive patients previously treated with peginterferon alfa-2a in 2 large randomized controlled trials were retrospectively analyzed. HBV RNA levels were measured using a real-time polymerase chain reaction assay. Ability of individual biomarkers to predict HBeAg seroconversion at 24 weeks posttreatment was evaluated using receiver operating characteristics (ROC) analyses. RESULTS: The study included 131 subjects (70% male, 96% Asians, 35% HBV genotypes B, and 61% C), 76 treated with peginterferon alfa-2a alone and 55 in combination with lamivudine. Median HBV RNA levels were significantly lower, at all timepoints, in patients achieving HBeAg seroconversion. Levels of HBV RNA at treatment weeks 12 and 24 showed good ability to predict HBeAg seroconversion (area under ROC scores >0.75, P < .001). A HBV RNA cutoff of >5.5 log10 copies/mL identified 30% of nonresponders at week 12 (negative predictive value >90%). CONCLUSION: Serum HBV RNA is an early predictor of HBeAg seroconversion in patients treated with peginterferon alfa-2a. CLINICAL TRIALS REGISTRATION: NCT01705704.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. van Bömmel F, van Bömmel A, Krauel A, et al. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis. 2018. PMID: 29741634. doi:10.1093/infdis/jiy270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。